ReviewFrontiers in oncology2026
Risk of malignancy and surveillance of premalignant gastrointestinal lesions in adult celiac disease.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Celiac disease is a systemic autoimmune affliction triggered by dietary gluten in genetically predisposed subjects. Current estimation of the prevalence of celiac disease is approximately 1% for the global population. These data are consistent with current figures from the Czech Republic (prevalence of 1.06% in 2023). Celiac disease can be associated with several complications including malignancy. Exact epidemiology data on T-cell lymphoma and small intestinal adenocarcinoma in the Czech Republic over the period 2010-2023 are also provided. Unlike the no-biopsy approach in children, despite current non-conclusive discussion and besides serology, upper gastrointestinal endoscopy, biopsies, and histology are mandatory for proper diagnosis and initial assessment of the severity of celiac disease in adults. However, there are so far no unified and integrated recommendations for the follow-up of adult celiac disease. Although the risk of malignancy in celiac disease is relatively low, especially in a strict gluten-free diet, it might nevertheless be further decreased by an individualized surveillance. Endoscopy controls with biopsies for histology, immunohistochemistry, and flow cytometry are essential. The purpose of this article was to review the risk and diagnostics of malignancy in celiac disease. A proposal for the individualized surveillance of premalignant gastrointestinal lesions in adult celiac disease was drafted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.